Published in World J Gastrointest Pathophysiol on February 15, 2013
Liver fibrosis. J Clin Invest (2005) 17.27
Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med (2008) 11.61
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 6.06
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A (2003) 5.08
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem (2002) 3.81
Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res (2001) 3.18
The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 2.99
Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest (1994) 2.81
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med (2001) 2.52
Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology (2002) 2.49
Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature (1995) 2.33
Inflammation and angiotensin II. Int J Biochem Cell Biol (2003) 2.22
Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology (2001) 1.91
A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology (2002) 1.90
Counterregulatory actions of angiotensin-(1-7). Hypertension (1997) 1.87
Angiotensin II and renal fibrosis. Hypertension (2001) 1.87
Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology (2010) 1.77
Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol (2005) 1.73
Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72
Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology (1996) 1.66
Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology (2001) 1.64
Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology (1999) 1.58
The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology (2002) 1.57
Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis. Gastroenterology (1994) 1.50
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology (2002) 1.50
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology (2009) 1.49
Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension (1996) 1.48
Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension (2005) 1.39
Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol (2006) 1.37
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol (2001) 1.35
Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology (2005) 1.34
In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension (1992) 1.31
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology (2004) 1.30
Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol (2003) 1.27
Mechanisms of extrahepatic vasodilation in portal hypertension. Gut (2008) 1.23
Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut (2005) 1.23
Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology (1993) 1.20
Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol (2007) 1.16
Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med (1996) 1.05
Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev (2003) 1.04
Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res (1998) 1.04
Production of angiotensin-(1-7) by human vascular endothelium. Hypertension (1992) 1.03
NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol (1999) 1.03
Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides (2006) 1.03
Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol (2003) 1.03
Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol (2001) 1.03
Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol (2008) 1.01
Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol (1994) 1.01
Reduced vascular sensitivity to norepinephrine in portal-hypertensive rats. Am J Physiol (1985) 1.01
Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) (2009) 1.01
Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology (2006) 1.00
Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol (2005) 0.99
Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol (2003) 0.99
The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol (2005) 0.99
Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut (1999) 0.98
Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis (1999) 0.98
ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol (2011) 0.97
Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis (1999) 0.97
Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol (2000) 0.95
Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology (2001) 0.95
Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. Hypertension (2000) 0.95
Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology (1999) 0.94
Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol (2005) 0.93
Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol (2007) 0.93
Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology (2003) 0.93
Cellular and molecular basis of portal hypertension. Clin Liver Dis (2001) 0.93
Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am (2010) 0.92
Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem (2006) 0.90
Are we poised to target ACE2 for the next generation of antihypertensives? J Mol Med (Berl) (2008) 0.90
Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology (2007) 0.90
Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther (1998) 0.90
Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney. Peptides (2012) 0.90
Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. Aliment Pharmacol Ther (2008) 0.90
Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med (2006) 0.89
Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosis. Eur J Clin Invest (2009) 0.89
Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: relationship with hemodynamic disturbances. J Hepatol (2001) 0.87
Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology (2000) 0.87
Pregnancy enhances the angiotensin (Ang)-(1-7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of Ang-(1-7). Endocrinology (2003) 0.87
In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol (1992) 0.87
Angiotensin-converting enzyme-2: a molecular and cellular perspective. Cell Mol Life Sci (2004) 0.87
Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol (2010) 0.85
Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. Crit Care Med (2005) 0.84
Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol (2008) 0.82
Role of endothelin in systemic and portal resistance in cirrhosis. Gut (2006) 0.81
Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin II and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver. Am J Physiol Gastrointest Liver Physiol (2012) 0.81
Portal vascular responsiveness to sympathetic stimulation and nitric oxide in cirrhotic rats. J Hepatol (1996) 0.80
Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptor-specific mechanism. Hepatology (2001) 0.80
Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol Gastrointest Liver Physiol (2009) 0.80
Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study. Eur J Gastroenterol Hepatol (2004) 0.78
New insights into the pathobiology of portal hypertension. Hepatol Res (2009) 0.78
Impaired agonist-dependent myosin phosphorylation and decreased RhoA in rat portal hypertensive mesenteric vasculature. Am J Physiol Gastrointest Liver Physiol (2004) 0.77
Vasoconstrictor responses are normal but prostanoid-mediated vasodilatation is enhanced in human cirrhotic mesenteric arteries. J Gastroenterol Hepatol (2005) 0.77
Fate of bradykinin on the rat liver when administered by the venous or arterial route. J Gastroenterol Hepatol (2005) 0.77
Second study shows that octreotide may prevent early rebleeding in cirrhosis. BMJ (1998) 0.76
Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. Hepatology (2004) 2.17
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology (2012) 1.96
Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust (2003) 1.86
Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust (2003) 1.84
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2006) 1.59
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology (2002) 1.50
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology (2007) 1.49
Management of healthcare workers after occupational exposure to hepatitis C virus. Med J Aust (2003) 1.49
Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation, and treatment. J Gastroenterol Hepatol (2013) 1.24
Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol (2007) 1.16
Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol (2006) 1.11
Liver fibrosis: a balance of ACEs? Clin Sci (Lond) (2007) 1.08
Muscle mass and mortality in chronic liver disease: the impact of testosterone. Liver Transpl (2014) 1.07
Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol (2010) 1.05
Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations. Hepatol Int (2011) 1.04
Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol (2008) 1.01
Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology (2004) 1.01
Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) (2009) 1.01
Risk factors for liver transplantation waiting list mortality. J Gastroenterol Hepatol (2007) 0.98
Differential bidirectional transfer of indinavir in the isolated perfused human placenta. Antimicrob Agents Chemother (2005) 0.97
Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl (2013) 0.97
Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver. Hepatol Int (2008) 0.96
A case of fulminant hepatic failure in pregnancy. Hepatology (2010) 0.94
Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. J Gastroenterol Hepatol (2004) 0.90
Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation. Clin Infect Dis (2009) 0.90
Hodgkin lymphoma and fulminant hepatic failure. Leuk Lymphoma (2010) 0.88
Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology (2013) 0.88
Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant (2009) 0.86
Acute allograft rejection in human liver transplant recipients is associated with signaling through toll-like receptor 4. J Gastroenterol Hepatol (2011) 0.86
Early-onset versus late-onset nonanastomotic biliary strictures post liver transplantation: risk factors reflect different pathogenesis. Transpl Int (2012) 0.85
Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer (2010) 0.84
Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond) (2012) 0.84
Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine. J Clin Virol (2004) 0.83
Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol (2008) 0.82
Risk factors for band-induced ulcer bleeding after prophylactic and therapeutic endoscopic variceal band ligation. Eur J Gastroenterol Hepatol (2015) 0.82
Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin II and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver. Am J Physiol Gastrointest Liver Physiol (2012) 0.81
Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol Gastrointest Liver Physiol (2009) 0.80
A novel method for determining hepatic sinusoidal oxygen permeability in the isolated perfused rat liver using [15O]O2. Nucl Med Biol (2003) 0.80
Liver transplant recipient selection: MELD vs. clinical judgment. Liver Transpl (2005) 0.79
A novel biomarker of immune function and initial experience in a transplant population. Transplantation (2014) 0.79
Effects of antibiotics on expression and function of Toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. J Hepatol (2009) 0.78
Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. Gut (2013) 0.78
Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome. J Gastroenterol Hepatol (2009) 0.78
Accidental paracetamol poisoning. Med J Aust (2007) 0.78
Time to review the selection criteria for transplantation in paracetamol-induced fulminant hepatic failure? Liver Transpl (2007) 0.77
Flucloxacillin-induced aplastic anaemia and liver failure. Transpl Int (2005) 0.77
Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. J Gastroenterol Hepatol (2007) 0.77
Paracetamol overdose in Victoria remains a significant health-care burden. J Gastroenterol Hepatol (2013) 0.77
Vasoconstrictor responses are normal but prostanoid-mediated vasodilatation is enhanced in human cirrhotic mesenteric arteries. J Gastroenterol Hepatol (2005) 0.77
Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: outcome of hepatorenal transplantation. Liver Transpl (2007) 0.77
Acute hepatic decompensation precipitated by pregnancy-related catabolic stress: a rare mimic of acute liver failure. Obstet Gynecol (2014) 0.76
Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol (2015) 0.76
To TOE or not to TOE? That is the question in patients with portal hypertension and varices. Gut (2012) 0.75
Disease recurrence after liver transplantation: need we worry? J Gastroenterol Hepatol (2002) 0.75
Serum phosphate as a predictor of outcome in acetaminophen-induced fulminant hepatic failure. Hepatology (2003) 0.75
Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressants. World J Gastroenterol (2012) 0.75
Endoscopic variceal ligation for primary prophylaxis of esophageal variceal hemorrhage in pre-liver transplant patients. Liver Transpl (2009) 0.75
The effect of oxygen supplementation on the arterial ketone body ratio in human cirrhosis. Digestion (2002) 0.75
Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant (2005) 0.75
Profiles of perfluoroalkyl substances in the liver and serum of patients with liver cancer and cirrhosis in Australia. Ecotoxicol Environ Saf (2013) 0.75
A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis (2014) 0.75
Low-serum testosterone levels pre-liver transplantation are associated with reduced rates of early acute allograft rejection in men. Transplantation (2014) 0.75
Hepatitis B: weighing the costs of treatment. J Gastroenterol Hepatol (2002) 0.75